Aims The most commonly mutated gene in vulvar squamous cell carcinoma (VSCC) is TP53 and its prognostic value, particularly in HPV-independent VSCC, is uncertain. In other tumours, p53 immunohistochemistry (IHC) is an excellent surrogate marker for TP53 mutations. In order to study this in VSCC, we assigned six p53 IHC patterns into two final classes: 'wild-type' or 'mutant'. We determined the performance and interobserver variability of this pattern-based p53 IHC approach.Methods and results Two experienced gynaecological pathologists scored the predefined p53 IHC patterns of 59 VSCC, independently and blinded for molecular data. Agreement was calculated by Cohen's kappa. All disagreements regarding p53 IHC patterns were resolved by a cons...
Meeting abstract from 17th Biennial Meeting of the International Gynecologic Cancer Society Kyoto, J...
Immunohistochemistry staining of p53 is a cheap and simple method to detect aberrant function of p53...
The tumour suppressor p53 is mutated in cancer, including over 96% of high-grade serous ovarian canc...
INTRODUCTION:The most commonly mutated gene in vulvar squamous cell carcinoma (VSCC) is TP53 and its...
Aims The most commonly mutated gene in vulvar squamous cell carcinoma (VSCC) is TP53 and its prognos...
The recent literature has shown that vulvar squamous cell carcinoma (VSCC) can be stratified into tw...
Human papillomavirus (HPV)-independent vulvar squamous cell carcinomas (VSCC) and its precursors fre...
Objective. There is great need for better risk stratification in vulvar squamous cell carcinoma (VSC...
TP53 mutations are considered a surrogate biomarker of the serous-like 'copy number high' molecular ...
TP53 mutations are ubiquitous in high-grade serous ovarian carcinomas (HGSOC), and the presence of T...
TP53 mutations are considered a surrogate biomarker of the serous‐like ‘copy number high’ molecular ...
Vulvar squamous cell cancer (VSC) accounts for 90% of vulvar cancers. Next-generation sequencing stu...
Human papillomavirus (HPV)-independent vulvar squamous cell carcinomas (VSCC) and its precursors fre...
FGFR3 mutations are frequently mutually exclusive of TP53 mutations in invasive high grade urothelia...
BACKGROUND/AIM: Diffuse and strong nuclear p53 immunoreactivity and a complete lack of p53 expressio...
Meeting abstract from 17th Biennial Meeting of the International Gynecologic Cancer Society Kyoto, J...
Immunohistochemistry staining of p53 is a cheap and simple method to detect aberrant function of p53...
The tumour suppressor p53 is mutated in cancer, including over 96% of high-grade serous ovarian canc...
INTRODUCTION:The most commonly mutated gene in vulvar squamous cell carcinoma (VSCC) is TP53 and its...
Aims The most commonly mutated gene in vulvar squamous cell carcinoma (VSCC) is TP53 and its prognos...
The recent literature has shown that vulvar squamous cell carcinoma (VSCC) can be stratified into tw...
Human papillomavirus (HPV)-independent vulvar squamous cell carcinomas (VSCC) and its precursors fre...
Objective. There is great need for better risk stratification in vulvar squamous cell carcinoma (VSC...
TP53 mutations are considered a surrogate biomarker of the serous-like 'copy number high' molecular ...
TP53 mutations are ubiquitous in high-grade serous ovarian carcinomas (HGSOC), and the presence of T...
TP53 mutations are considered a surrogate biomarker of the serous‐like ‘copy number high’ molecular ...
Vulvar squamous cell cancer (VSC) accounts for 90% of vulvar cancers. Next-generation sequencing stu...
Human papillomavirus (HPV)-independent vulvar squamous cell carcinomas (VSCC) and its precursors fre...
FGFR3 mutations are frequently mutually exclusive of TP53 mutations in invasive high grade urothelia...
BACKGROUND/AIM: Diffuse and strong nuclear p53 immunoreactivity and a complete lack of p53 expressio...
Meeting abstract from 17th Biennial Meeting of the International Gynecologic Cancer Society Kyoto, J...
Immunohistochemistry staining of p53 is a cheap and simple method to detect aberrant function of p53...
The tumour suppressor p53 is mutated in cancer, including over 96% of high-grade serous ovarian canc...